Insulin glargine joint repaglinide of treating 68 cases of type 2 diabetes

Objective To observe the clinical efficacy and safety analysis of insulin glargine joint repaglinide of treating type 2 diabetes. Methods 138 patients with type 2 diabetes who were randomly divided into two groups,the control group and the treatment group were 68 cases,patients in both groups stop taking hypoglycemic drugs before,on the basis of the diet,exercise and psychotherapy.The control group were given protamine biosynthetic human insulin 30 R(Novolin 30 R)points early,late 2 times 30 minutes before a meal subcutaneous injection;The treatment group received insulin glargine (Lantus),22:00 subcutaneous injection,1 time a day, repaglinide tablets(repaglinide),the initial dose of 0.5-1 mg,3 times a day, before a meal 20minute oral,both groups were treated for 12 weeks. Results After treatment,the incidence of hypoglycemia was significantly lower than the control group(P 0.05); 2 groups after treatment and before treatment in FBG 2hPG,HbA1C comparison,were significantly reduced (P 0.01);After treatment the treatment group and the control groups in FBG was no significant difference(P 0.05),After the treatment,compared with the two groups in 2hPG,HbA1C,the treatment group was significantly better than the control group(P 0.05 or 0.01). Conclusion The insulin glargine United repaglinide had clear efficacy,low incidence of hypoglycemia and high security in treatment of type 2 diabetes.